Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNA Ginkgo Bioworks	$12.51 +6.4%	$11.55	$5.00 ▼ $16.85	$742.96M	1.5	1.54 million shs	1.73 million shs
GYRE Gyre Therapeutics	$8.18 +8.3%	$7.59	$6.11 ▼ $19.00	$787.84M	1.8	80,965 shs	104,899 shs
MNMD Mind Medicine (MindMed)	$10.19 +3.8%	$8.52	$4.70 ▼ $10.49	$775.34M	2.49	1.12 million shs	1.74 million shs
SXTC China SXT Pharmaceuticals	$1.57	$1.68	$0.95 ▼ $7.84	$182.16M	1.24	39,235 shs	17,398 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNA Ginkgo Bioworks	0.00%	-4.95%	-16.14%	+78.94%	-17.71%
GYRE Gyre Therapeutics	0.00%	+0.49%	+10.84%	-5.76%	-31.61%
MNMD Mind Medicine (MindMed)	0.00%	+6.04%	+4.84%	+39.59%	+58.97%
SXTC China SXT Pharmaceuticals	0.00%	-2.48%	-3.09%	+1.29%	-77.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNA Ginkgo Bioworks	1.0632 of 5 stars	1.5	3.0	1.2	2.5	0.6
GYRE Gyre Therapeutics	0.0276 of 5 stars	0.0	1.0	1.4	0.0	0.0
MNMD Mind Medicine (MindMed)	2.8275 of 5 stars	3.6	3.0	3.1	0.8	0.6
SXTC China SXT Pharmaceuticals	0.7401 of 5 stars	0.0	3.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNA Ginkgo Bioworks	3.00	Buy	$10.00	-20.05% Downside
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
MNMD Mind Medicine (MindMed)	3.22	Buy	$24.71	142.53% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SXTC, DNA, GYRE, and MNMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	DNA Ginkgo Bioworks	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/4/2025	MNMD Mind Medicine (MindMed)	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$25.00
8/1/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNA Ginkgo Bioworks	$227.04M	3.26	N/A	N/A	$13.17 per share	0.95
GYRE Gyre Therapeutics	$105.76M	7.45	$0.20 per share	41.42	$1.05 per share	7.79
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$3.21 per share	N/A
SXTC China SXT Pharmaceuticals	$1.74M	104.69	N/A	N/A	$21.35 per share	0.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNA Ginkgo Bioworks	-$547.03M	-$5.86	0.00	N/A	N/A	-136.56%	-43.25%	-22.29%	11/11/2025 (Estimated)
GYRE Gyre Therapeutics	$12.09M	$0.01	163.60	∞	N/A	4.08%	7.67%	6.19%	11/12/2025 (Estimated)
MNMD Mind Medicine (MindMed)	-$108.68M	-$1.53	0.00	N/A	N/A	N/A	-50.24%	-39.41%	11/6/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SXTC, DNA, GYRE, and MNMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	GYRE Gyre Therapeutics	$0.03	$0.02	-$0.01	$0.04	$30.80 million	$26.77 million
8/7/2025	Q2 2025	DNA Ginkgo Bioworks	-$1.44	-$1.10	+$0.34	-$1.10	$41.60 million	$49.60 million
7/31/2025	Q2 2025	MNMD Mind Medicine (MindMed)	-$0.38	-$0.50	-$0.12	-$0.50	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNA Ginkgo Bioworks	N/A	5.41	5.41
GYRE Gyre Therapeutics	N/A	5.40	4.87
MNMD Mind Medicine (MindMed)	0.22	4.98	4.98
SXTC China SXT Pharmaceuticals	0.01	3.54	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNA Ginkgo Bioworks	78.63%
GYRE Gyre Therapeutics	23.99%
MNMD Mind Medicine (MindMed)	27.91%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
DNA Ginkgo Bioworks	9.72%
GYRE Gyre Therapeutics	10.00%
MNMD Mind Medicine (MindMed)	2.26%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNA Ginkgo Bioworks	640	59.20 million	53.45 million	Optionable
GYRE Gyre Therapeutics	40	96.31 million	86.68 million	No Data
MNMD Mind Medicine (MindMed)	40	76.09 million	74.37 million	Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable

SXTC, DNA, GYRE, and MNMD Headlines

Recent News About These Companies

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Up 48.3% in July

August 21 at 9:40 AM | marketbeat.com

Wall Street Zen Upgrades China SXT Pharmaceuticals (NASDAQ:SXTC) to Hold

August 3, 2025 | marketbeat.com

China SXT Pharmaceuticals Full Year 2025 Earnings: US$2.32 loss per share (vs US$28.58 loss in FY 2024)

August 2, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Inc. (SXTC) Stock Price Today - WSJ

July 30, 2025 | wsj.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Trading Down 1.3% - What's Next?

July 30, 2025 | marketbeat.com

China SXT Pharmaceuticals, Inc. (SXTC) - Yahoo Finance

July 4, 2025 | sg.finance.yahoo.com

China SXT Pharmaceuticals Inc News (SXTC) - Investing.com

June 25, 2025 | investing.com

China SXT Pharmaceuticals Issues 90 Million Shares Following Warrant Exercise

June 16, 2025 | tipranks.com

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.comM

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, DNA, GYRE, and MNMD Company Descriptions

Ginkgo Bioworks NYSE:DNA

$12.51 +0.75 (+6.36%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$12.70 +0.19 (+1.54%)

As of 08/22/2025 07:44 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Gyre Therapeutics NASDAQ:GYRE

$8.18 +0.63 (+8.34%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$8.18 0.00 (0.00%)

As of 08/22/2025 04:10 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Mind Medicine (MindMed) NASDAQ:MNMD

$10.19 +0.37 (+3.77%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$10.18 0.00 (-0.05%)

As of 08/22/2025 07:54 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.57 0.00 (0.00%)

Closing price 08/22/2025 03:55 PM Eastern

Extended Trading

$1.57 +0.00 (+0.25%)

As of 08/22/2025 04:12 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time